The 7th report from Lord O'Neil's AMR review is aligned with NAMRIP's founding philosophy

The philosophy on which NAMRIP was founded, of tackling AMR by more than simply the introduction of new drugs, has been supported in the release today of Lord O’Neil’s seventh report, entitled “22 March 2016 - Infection prevention, control and surveillance: Limiting the development and spread of drug-resistance”.

NAMRIP’s founder Professor Timothy Leighton said: “Lord O’Neil’s review body has really crystallized the landscape and galvanized the scientific and medical communities in the fight against AMR. His first report inspired me to take action and set up NAMRIP, and I am delighted that this seventh report chimes so well with all that NAMRIP members have been achieving. I am immensely proud of the inspired hard work done by the members of NAMRIP. One only has to read the abstract of the report to see that the road we set along, of forging new collaborations across disciplines to look at infection prevention and control; provision of appropriate water, food and sanitation; the use of, and changes required in, materials and attitudes, is recognized in this report as fundamental to tackling AMR, and must be addressed to complement therapies and vaccines.”

The abstract of the report is as follows:

‘This report examines the central role that infection prevention, control, and surveillance need to play in combatting the rise of drug-resistant infections. This is based on the recognition that fundamental improvements in these areas are the key to sustainable gains in health outcomes, and yet are often given insufficient attention in our response to the global challenges of rising drug resistance. The paper looks first at the role of infection prevention in the community through improved water and sanitation infrastructure. It then looks at the need to prevent and control of infections in health and care settings. Finally, it looks at monitoring resistant infections through surveillance systems that will provide valuable information for doctors, patients as well global and national policymakers.’